Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/16—Central respiratory analeptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• A represents either a group of general formula NR x in which R x represents either a hydrogen atom or a (Ci-C,) linear or branched alkyl group optionally substituted by one or more fluorine atoms, or a group (C 4 -C 7 ) cycloalkyl, either a (C 3 -C 7 ) cycloalkyl- (C 1 -C 3 ) alkyl group, or a phenyl (C 3 -C 3 ) alkyl group optionally substituted by one or two hydroxy groups or methoxy, either a (C 2 -C 4 ) alkenyl group, or a (C 2 -C 4 ) alkynyl group, or a group of general formula N + (0 " ) R 1 in which R x is as defined ci above, or again a group of general formula N + (R ') R 1 in which R' represents a (C 1 -C 7 ) linear or branched alkyl
• R 2 represents either a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, (C 1 -C 4 ) alkyl groups,
• (C 1 -C 4 ) alkoxy amino of general formula NR 3 R 4 in which R 3 and R 4 each represent, independently of one another, a hydrogen atom or a group (C 1 -C 4 ) alkyl, or form with the nitrogen atom which carries them a cycle pyrrolidine, piperidine or morpholine, or a phenyl group optionally substituted by an atom or a group as defined for the symbol X above.
• the compounds of general formula (I) can exist in the form of the threo racemate ⁇ 1R, 2R; 1S, 2S) or in the form of (1J, 2J?) Or (1S, 2S) enantiomers; they can exist in the form of free bases or of addition salts with acids.
• the compounds of the invention exhibit a particular activity as specific inhibitors of the glycine transporters glytl and / or glyt2.
• the compounds preferred as inhibitors of the glytl transporter are of configuration (1S, 2S) with R 2 representing one or more halogen atoms or trifluoromethyl groups, while the compounds preferred as inhibitors of the glyt2 transporter are of configuration (1R, 2.R ) with R 2 representing a halogen atom and an amino group of general formula NR 3 R 4 .
• a diamine of general formula (II) is coupled, in which R x and X are as defined above (with R x different from a hydrogen atom) with an activated acid or a chloride of acid of general formula (III) in which Y represents a nucleofuge group, such as a halogen atom and R 2 is as defined above, using the methods known to those skilled in the art.
• the diamine of general formula (II) can be prepared by a process illustrated by scheme 2 which follows.
• the einreb amide of formula (IV) is reacted with the phenyllithium derivative of general formula (V), in which X is as defined above, in an ethereal solvent such as diethyl ether, between -30 ° C and room temperature; a ketone of general formula (VI) is obtained which is reduced to alcohol of threo configuration of general formula (VII) by a reducing agent such as K-Selectride® or L-Selectride® (tri-sec-butylborohydride of potassium or lithium), in an ethereal solvent such as tetrahydrofuran, between -78 ° C and room temperature.
• a reducing agent such as K-Selectride® or L-Selectride® (tri-sec-butylborohydride of potassium or lithium
• the diamine of general formula (II) is obtained in which R ⁇ _ represents a methyl group and X represents a hydrogen atom in the form of a mixture of the two threo / erythro 9/1 diastereoisomers. It can be salified, for example with oxalic acid, then purified by recrystallization of the oxalate formed in a mixture of alcohol and an ethereal solvent such as methanol and diethyl ether, to obtain the threo diastereoisomer. ⁇ 1R, 2R; 1S, 2 S) pure.
• Another method consists, according to scheme 2, in using a compound of general formula (I) in which R ⁇ represents either an optionally substituted phenylmethyl group, and in deprotecting the nitrogen from the piperidine ring, for example by an oxidizing agent or by a Lewis acid such as boron tribromide, or by hydrogenolysis, either an alkenyl group, preferably an allyl group, followed by deprotection with a Pd ° complex, to obtain a compound of general formula (I) in which R x represents a hydrogen atom.
• the compounds of general formula (I) in which A represents a group of general formula N + (0 ⁇ ) R x can be prepared from the compounds of general formula (I) in which A represents a group of general formula NR- L , in which R x is as described above, by reaction with an oxidizing agent, for example 3-chloroperbenzoic acid, in a chlorinated solvent such as dichloromethane, at a temperature between 0 ° C and ambient.
• an oxidizing agent for example 3-chloroperbenzoic acid
• the compounds of general formula (I) in which A represents a group of general formula N + (R ') R 1 can be prepared from compounds of general formula (I) in which A represents a group of general formula NR x , by reaction with an alkyl halide of general formula R'-Z, in which R 'is as defined above and Z represents a halogen atom, in a polar solvent such as acetonitrile, at a temperature between ambient and 100 ° C.
• the chiral compounds of general formula (I) corresponding to the enantiomers (1R, 2R) or (1S, 2S) of the threo diastereoisomer can also be obtained by separation of the racemic compounds by high performance liquid chromatography (HPLC) on a chiral column.
• the Weinreb amide of racemic or chiral formula (IV) can be prepared according to a method analogous to that described in Eur. J. Med. Chem. , 35, (2000), 979-988 and J. Med. Chem. , 41, (1998), 591-601.
• the phenyllithium compound of general formula (V) where X represents a hydrogen atom is commercially available. Its substituted derivatives can be prepared according to a method analogous to that described in Tetra. Lett. , 57, 33, (1996), 5905-5908. The according to a method analogous to that described in patent application EP-0366006.
• the amine of general formula (IX) in which X represents a hydrogen atom can be prepared in chiral series according to a method described in patent US-2928835.
• the amine of general formula (XIII) can be prepared according to a method analogous to that described in Chem. Pharm. Bull. , 32, 12, (1984), 4893-4906 and Synthesis, (1976), 593-595.
• the acids and acid chlorides of general formula (III) are commercially available, except in the case of 4-amino-3-chloro-5-trifluoromethylbenzoic acid.
• the latter can be prepared by chlorination of 4-amino-5-trifluoromethylbenzoic acid with sulfuryl chloride in a chlorinated solvent such as chloroform, according to a method analogous to that described in Arzneim. Forsch. , 34, lia, (1984), 1668-1679.
• the dash "-” is part of the word, and the dash “_” is only used for the break at the end of the line; it must be deleted in the absence of a break, and must not be replaced either by a normal dash or by a space.
• the mixture is hydrolyzed with 16 ml of water and 16 ml of a 35% aqueous solution of hydrogen peroxide, and the mixture is allowed to return to room temperature with stirring for 2 h. It is diluted with water and ethyl acetate, the aqueous phase is separated, and it is extracted with ethyl acetate. After washing the combined organic phases, drying over sodium sulfate and evaporation of the solvent under reduced pressure, the residue is purified by chromatography on a column of silica gel, eluting with a mixture of ethyl acetate and cyclohexane. 2.0 g of oily product are obtained. 1.3. threo-phenyl (piperidin-2-yl) methanol.
• threo- (1-ethylpiperidin-2-yl) phenylmethanamine 0.8 g (3.65 mmol) of threo (1-ethylpiperidin-2-yl) phenylmethanol and 0.48 ml (3.65 mmol) are introduced into a 100 ml flask under an argon atmosphere.
• triethyl ine in 20 ml of anhydrous dichloromethane the mixture is cooled to 0 ° C., 0.28 ml (3.63 mmol) of methanesulfonyl chloride is added and the mixture is allowed to slowly return to room temperature for 2 h and the concentrates under reduced pressure.
• oily product 0.25 g is obtained. The latter is dissolved in a few ml of propan-2-ol, 5.9 ml of a 0.1N solution of hydrochloric acid in propan-2-ol are added, and the mixture is concentrated under reduced pressure in order to reduce the volume of the solvent. After trituration, 0.15 g of hydrochloride is finally isolated in the form of a white solid. Melting point: 230-232 ° C.
• Liquefied ammonia is introduced into an autoclave fitted with a magnetic stirrer and cooled to -50 ° C., a solution of the crude methanesulfonate previously prepared in solution in 30 ml of absolute ethanol is added, the autoclave is closed and maintains agitation for 48 h.
• the mixture is transferred to a flask and the amine is isolated in the form of an oily product which is used as it is in the following step.
• the ethanol is evaporated off under reduced pressure, the residue is extracted with dichloromethane, the aqueous phase is separated, an ammonia solution is added thereto and it is extracted with dichloromethane. After washing the combined organic phases, drying over sodium sulfate, filtration and evaporation of the solvent under reduced pressure, one obtains
• the ethanedioate is prepared by dissolving these 6.7 g of base in methanol, by the action of two equivalents of ethanedioic acid dissolved in the minimum amount of methanol.
• the salt obtained is purified by recrystallization from a mixture of methanol and diethyl ether. Finally, 4.7 g of ethanedioate from the pure threo diastereoisomer are isolated. Melting point: 156-159 ° C.
• Example 5 (Compound No. 36). ⁇ Threo-2-chloro-IV hydrochloride [phenyl (piperidin-2-yl) _ methyl] -3-trifluoromethylbenzamide 1: 1.
• Threo-2-chloro-.W- [phenyl (piperidin-2-yl) ethyl] -3-trifluoromethylbenzamide hydrochloride 1 1. A solution of 4.17 g (10 mmol) of 2-chloro-IV- [phenyl (pyridin-2-yl) methyl] - 3-trifluoromethylbenzamide in 43 ml of glacial acetic acid is placed in a Parr flask. 0.1 g of 5% palladium on carbon is added and hydrogenation is carried out at 0.35 Mpa at 50 ° C. for 3 h.
• the catalyst is removed by filtration, the filtrate is concentrated under reduced pressure, the residue is taken up with water and ethyl acetate, concentrated sodium hydroxide is added and the mixture is extracted several times with ethyl acetate.
• the organic phase is washed with water and then with a saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and the solvent is evaporated off under reduced pressure.
• the residue is purified by two successive chromatographies on a column of silica gel, eluting with a 100/0 to 95/5 mixture of dichloromethane and methanol, in order to separate the starting product which has not reacted.
• 0.8 g of the threo (less polar) diastereoisomer are isolated.
• the hydrochloride is prepared by dissolving it in a few ml of propan-2-ol and adding 20 ml of a 0.1N solution of hydrochloric acid in propan-2-ol to it. The solvent is partially evaporated under reduced pressure, a white solid is obtained by trituration, it is collected by filtration and dried under reduced pressure. 0.6 g of hydrochloride is finally obtained. Melting point: 234-235 ° C.
• Example 7 (Compounds No. 69 and 70). 2-Chloro-IV - [[1-methyl-1-oxido-piperidin-2-yl] (phenyl) _ methyl] -3-trifluoromethylbenzamide.
• Example 8 (Compound No. 71). (2S) -2 [(1S) - [[2-chloro-3- (trifluoromethyl) _ benzoyl] amino] (phenyl) methyl] -1, 1-dimethylpiperidinium iodide.
• N-CH 3 H 3 4-F N-CH 3 H 3 H N-CH 3 H 5 2-C1 N-CH 3 H 5 2-C1 N-CH 3 H 5 2-C1 N-CH 3 H 3 5 -CF 3 N-CH 3 H 3 2-C1 N-CH 3 H 3 2-C1 N-CH 3 H 3 2-C1 N-CH 3 H 3 4-C1 N-CH 3 H 5 2-F, 3 -C1 N-CH 3 H 5 2-F N-CH 3 H 5 2-OCH 3 , 4-C 6 H 5 N-CH 3 H 5 3-C1, 4-NH 2 N-CH 3 H 5 3- C1, 4-NH 2 N-CH 3 2-CH 3 3- C1, 4-NH 2 N-CH 3 2-CH 3 3- C1, 4-NH 2 N-CH 3 2-CH 3 2-C1 N-CH 3 H 3 2, 6-Cl 2 N-CH 3 H 3 2, 6-Cl 2 N-CH, 4 -F 3 2-C1
• the compounds of the invention have been subjected to a series of pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
• glycine transport in SK-N-MC cells expressing the native glytl human transporter The uptake of [ 14 C] glycine is studied in SK-N-MC cells (human neuroepithelial cells) expressing the native glytl human transporter by measuring the radioactivity incorporated in the presence or absence of the test compound.
• the cells are cultured in a monolayer for 48 h in plates pretreated with 0.02% fibronectin. On the day of the experiment, the culture medium is eliminated and the cells are washed with a Krebs-HEPES buffer ([4- (2-hydroxyethyl) piperazine-1-ethanesulfonic acid) at pH 7.4.
• Krebs-HEPES buffer [4- (2-hydroxyethyl) piperazine-1-ethanesulfonic acid
• the compounds of the invention in this test, have an IC 50 of the order of 0.0001 to 10 ⁇ M.
• Increasing doses of the compound to be studied are administered orally (preparation by trituration of the molecule to be tested in a mortar in a Tween / Methocel TM solution at 0.5% in distilled water) or intraperitoneally (dissolution of the test molecule in physiological saline or preparation by trituration in a mortar in a solution 0.5% Tween / methocel in water, depending on the solubility of the molecule) on male OFl Iffa Credo mice of 20 to 25 g on the day of the experiment.
• the control group is treated by the vehicle.
• the doses in mg / kg, the route of administration and the treatment time are determined according to the molecule to be studied.
• each animal is quickly removed on ice, weighed. and stored at 4 ° C or frozen at -80 ° C (in both cases the samples are kept for 1 day maximum).
• Each sample is homogenized in a Krebs-HEPES buffer at pH 7.4 at a rate of 10 ml / g of tissue. 20 ⁇ l of each homogenate are incubated for 10 min at room temperature in the presence of 10 mM L-alanine and buffer. The non-specific uptake is determined by adding 10 mM glycine to the control group.
• the reaction is stopped by vacuum filtration and the radioactivity retained is estimated by solid scintillation by counting on a Microbeta Tri-lux TM counter.
• An inhibitor of [ 14 C] glycine uptake will decrease the amount of radioligand incorporated into each homogenate.
• the activity of the compound is evaluated by its ED 50 , a dose which inhibits 50% of the capture of [ 14 C] glycine compared to the control group.
• the most powerful compounds of the invention, in this test have an ED 50 of 0.1 to 5 mg / kg intraperitoneally or orally.
• the effectiveness of the compound is determined by the IC 50 concentration capable of decreasing the specific glycine uptake by 50%, defined by the difference in radioactivity incorporated by the control batch and the batch which received the 10 mM glycine.
• the compounds of the invention in this test have an IC 50 of the order of 0.0001 to 10 ⁇ M.
• test compound Increasing doses of the test compound are administered orally (preparation by trituration of the test compound in a mortar, in a Tween / Methocel TM solution at 0.5% in distilled water) or intraperitoneal (test compound dissolved in physiological saline, or triturated in a mortar, in a Tween / Methocel TM solution at 0.5% in distilled water) to male OFl Iffa Credo mice of 20 to 25 g on the day of the experiment .
• the control group is treated by the vehicle.
• the doses in mg / kg, the route of administration, the treatment time and the euthanasia time are determined according to the compound to be studied.
• the marrow is quickly removed, weighed and placed in glass scintillation vials, stored in crushed ice or frozen at -80 ° C (in both cases the samples are kept for 1 day maximum).
• Each sample is homogenized in a Krebs-HEPES buffer at pH 7.4, at a rate of 25 ml / g of tissue. 50 ⁇ l of each homogenate are incubated for 10 min at room temperature in the presence of buffer. The non-specific uptake is determined by adding 10 mM glycine to the control group.
• the reaction is stopped by vacuum filtration and the radioactivity is estimated by solid scintillation by counting on a Microbeta Tri-lux TM counter.
• An inhibitor of [ 1 C] glycine uptake will decrease the amount of radioligand incorporated into each homogenate.
• the activity of the compound is evaluated by its ED 50 , an effective dose which inhibits 50% of the capture of [ 14 C] glycine compared to the control group.
• the best compounds of the invention have, in this test, an ED 50 of 1 to 20 mg / kg, intraperitoneally or orally.
• the compounds of the invention can be used for the treatment of behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficit form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics.
• schizophrenia deficit form and productive form
• extrapyramidal symptoms induced by neuroleptics for the treatment of various forms of anxiety, panic attacks, phobias, obsessive-compulsive disorder compulsive
• various forms of depression including psychotic depression
• disorders due to alcohol abuse or withdrawal sexual behavior disorders
• eating disorders and for migraine treatment.
• the compounds of the invention can be used for the treatment of painful muscular contractures in rheumatology and in acute spinal pathology, for the treatment of spastic contractures of medullary or cerebral origin, for the symptomatic treatment of acute and subacute pains mild to moderate intensity, for the treatment of severe and / or chronic pain, neurogenic pain and rebellious pain, for the treatment of Parkinson's disease and parkinsonian symptoms of neurodegenerative origin or induced by neuroleptics, for the treatment generalized primary and secondary epilepsies, partial with simple or complex symptomatology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or as monotherapy, for the treatment of sleep apnea, and for neuroprotection.
• the present invention also relates to pharmaceutical compositions containing an effective dose of at least one compound according to the invention, in the base state or of a pharmaceutically acceptable salt or solvate, and as a mixture, as the case may be. if necessary, with suitable excipients. Said excipients are chosen according to the pharmaceutical form and the desired mode of administration.
• compositions according to the invention can thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, rectal, intraoccular administration.
• the unit forms of administration can be, for example, tablets, capsules, granules, powders, oral or injectable solutions or suspensions, transdermal patches ("patch"), suppositories.
• patch transdermal patches
• suppositories for topical administration, ointments, lotions and eye drops can be considered.
• Said unit forms are dosed to allow daily administration of 0.01 to 20 mg of active principle per kg of body weight, depending on the dosage form.
• a pharmaceutical carrier can be added to the active principle, micronized or not, which can be composed of diluents, such as, for example, lactose, microcrystalline cellulose, starch, and formulation adjuvants such as binders, (polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.), flow agents such as silica, lubricants such as magnesium stearate, stearic acid, glycerol tribehenate, sodium stearyl fumarate. Wetting agents or surfactants such as sodium lauryl sulfate can also be added.
• diluents such as, for example, lactose, microcrystalline cellulose, starch
• formulation adjuvants such as binders, (polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.)
• flow agents such as silica
• lubricants such as magnesium stearate, stearic acid, glycerol tribehenate, sodium ste
• the production techniques can be direct compression, dry granulation, wet granulation or hot melting.
• the tablets can be naked, coated, for example with sucrose, or coated with various polymers or other suitable materials. They can be designed to allow rapid, delayed or prolonged release of the active ingredient using polymer matrices or specific polymers used in the coating.
• the active principle is mixed with dry pharmaceutical vehicles (simple mixing, dry or wet granulation, or hot fusion), liquids or semi-solids.
• the capsules can be hard or soft, film-coated or not, so as to have rapid, prolonged or delayed activity (for example for an enteric form).
• a composition in the form of a syrup or elixir or for administration in the form of drops may contain the active principle together with a sweetener, preferably calorie-free, methylparaben or propylparaben as an antiseptic, a flavoring agent and a coloring agent.
• a sweetener preferably calorie-free, methylparaben or propylparaben as an antiseptic, a flavoring agent and a coloring agent.
• the powders and granules dispersible in water may contain the active principle in admixture with dispersing agents or wetting agents, or dispersing agents such as polyvinylpyrrolidone, as well as with sweeteners and flavor correcting agents.
• Suppositories prepared with binders that melt at the rectal temperature for example cocoa butter or polyethylene glycols, are used for rectal administration.
• aqueous suspensions For parenteral administration, aqueous suspensions, isotonic saline solutions or sterile injectable solutions containing pharmacologically compatible dispersing agents and / or wetting agents, for example propylene glycol or butylene glycol, are used.
• pharmacologically compatible dispersing agents and / or wetting agents for example propylene glycol or butylene glycol
• the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives, or else with a polymer matrix or with a cyclodextrin (transdermal patches, sustained-release forms).
• compositions according to the invention comprise a medium compatible with the skin. They may be in particular in the form of aqueous, alcoholic or hydroalcoholic solutions, gels, water-in-oil or oil-in-water emulsions having the appearance of a cream or gel, microemulsions, d aerosols, or in the form of vesicular dispersions containing ionic and / or nonionic lipids. These dosage forms are prepared according to the usual methods of the fields considered.
• compositions according to the invention may contain, alongside a compound of general formula (I), other active ingredients which may be useful in the treatment of the disorders and diseases " indicated above.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Anesthesiology (AREA)
• Addiction (AREA)
• Hospice & Palliative Care (AREA)
• Psychology (AREA)
• Rheumatology (AREA)
• Pulmonology (AREA)
• Hydrogenated Pyridines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyridine Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=28686193

Family Applications (1)

Country Status (35)

Cited By (26)

Families Citing this family (11)

Citations (4)

Family Cites Families (1)

• 2002
  • 2002-04-19 FR FR0204916A patent/FR2838739B1/fr not_active Expired - Fee Related
• 2003
  • 2003-04-15 AR ARP030101310A patent/AR039413A1/es unknown
  • 2003-04-17 ME MEP-256/08A patent/MEP25608A/xx unknown
  • 2003-04-17 DE DE60313602T patent/DE60313602T2/de not_active Expired - Lifetime
  • 2003-04-17 RS YU91404A patent/RS51888B/sr unknown
  • 2003-04-17 CA CA002481461A patent/CA2481461C/en not_active Expired - Fee Related
  • 2003-04-17 PL PL03373195A patent/PL373195A1/xx not_active IP Right Cessation
  • 2003-04-17 UA UA20041008110A patent/UA78025C2/uk unknown
  • 2003-04-17 BR BR0309397-2A patent/BR0309397A/pt not_active IP Right Cessation
  • 2003-04-17 JP JP2003586132A patent/JP4597532B2/ja not_active Expired - Fee Related
  • 2003-04-17 ES ES03740634T patent/ES2286444T3/es not_active Expired - Lifetime
  • 2003-04-17 AU AU2003262420A patent/AU2003262420B2/en not_active Ceased
  • 2003-04-17 MX MXPA04010326A patent/MXPA04010326A/es active IP Right Grant
  • 2003-04-17 KR KR10-2004-7016718A patent/KR20040103973A/ko not_active Ceased
  • 2003-04-17 KR KR1020087018794A patent/KR101019313B1/ko not_active Expired - Fee Related
  • 2003-04-17 US US10/511,886 patent/US7326722B2/en not_active Expired - Fee Related
  • 2003-04-17 PT PT03740634T patent/PT1499589E/pt unknown
  • 2003-04-17 SI SI200330893T patent/SI1499589T1/sl unknown
  • 2003-04-17 IL IL16440003A patent/IL164400A0/xx unknown
  • 2003-04-17 AT AT03740634T patent/ATE361279T1/de active
  • 2003-04-17 EA EA200401172A patent/EA007225B1/ru not_active IP Right Cessation
  • 2003-04-17 WO PCT/FR2003/001232 patent/WO2003089411A1/fr not_active Ceased
  • 2003-04-17 DK DK03740634T patent/DK1499589T3/da active
  • 2003-04-17 EP EP03740634A patent/EP1499589B1/fr not_active Expired - Lifetime
  • 2003-04-17 CN CNB038140063A patent/CN100482646C/zh not_active Expired - Fee Related
  • 2003-04-17 HR HR20040977A patent/HRP20040977B1/xx not_active IP Right Cessation
  • 2003-04-17 NZ NZ536015A patent/NZ536015A/en not_active IP Right Cessation
  • 2003-04-18 TW TW092109074A patent/TWI306402B/zh not_active IP Right Cessation
• 2004
  • 2004-09-30 IS IS7479A patent/IS2540B/is unknown
  • 2004-10-04 IL IL164400A patent/IL164400A/en not_active IP Right Cessation
  • 2004-10-07 MA MA27892A patent/MA27192A1/fr unknown
  • 2004-10-08 ZA ZA200408154A patent/ZA200408154B/en unknown
  • 2004-10-14 CO CO04103284A patent/CO5631432A2/es not_active Application Discontinuation
  • 2004-10-15 NO NO20044388A patent/NO329065B1/no not_active IP Right Cessation
  • 2004-10-18 TN TNP2004000208A patent/TNSN04208A1/fr unknown
  • 2004-10-18 EC EC2004005369A patent/ECSP045369A/es unknown
• 2007
  • 2007-04-03 US US11/695,912 patent/US20070197601A1/en not_active Abandoned
  • 2007-07-24 CY CY20071100988T patent/CY1108025T1/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events